452 related articles for article (PubMed ID: 33683917)
1. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
Fowler NH; Samaniego F; Jurczak W; Ghosh N; Derenzini E; Reeves JA; Knopińska-Posłuszny W; Cheah CY; Phillips T; Lech-Maranda E; Cheson BD; Caimi PF; Grosicki S; Leslie LA; Chavez JC; Fonseca G; Babu S; Hodson DJ; Shao SH; Burke JM; Sharman JP; Law JY; Pagel JM; Miskin HP; Sportelli P; O'Connor OA; Weiss MS; Zinzani PL
J Clin Oncol; 2021 May; 39(15):1609-1618. PubMed ID: 33683917
[TBL] [Abstract][Full Text] [Related]
2. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
3. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
Flinn IW; Miller CB; Ardeshna KM; Tetreault S; Assouline SE; Mayer J; Merli M; Lunin SD; Pettitt AR; Nagy Z; Tournilhac O; Abou-Nassar KE; Crump M; Jacobsen ED; de Vos S; Kelly VM; Shi W; Steelman L; Le N; Weaver DT; Lustgarten S; Wagner-Johnston ND; Zinzani PL
J Clin Oncol; 2019 Apr; 37(11):912-922. PubMed ID: 30742566
[TBL] [Abstract][Full Text] [Related]
4. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
Davids MS; O'Connor OA; Jurczak W; Samaniego F; Fenske TS; Zinzani PL; Patel MR; Ghosh N; Cheson BD; Derenzini E; Brander DM; Reeves JA; Knopińska-Posłuszny W; Allan JN; Phillips T; Caimi PF; Lech-Maranda E; Burke JM; Agajanian R; Pettengell R; Leslie LA; Cheah CY; Fonseca G; Essell J; Chavez JC; Pagel JM; Sharman JP; Hsu Y; Miskin HP; Sportelli P; Weiss MS; Flinn IW
Blood Adv; 2021 Dec; 5(23):5332-5343. PubMed ID: 34547767
[TBL] [Abstract][Full Text] [Related]
5. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Mato AR; Ghosh N; Schuster SJ; Lamanna N; Pagel JM; Flinn IW; Barrientos JC; Rai KR; Reeves JA; Cheson BD; Barr PM; Kambhampati S; Lansigan F; Pu JJ; Skarbnik AP; Roeker L; Fonseca GA; Sitlinger A; Hamadeh IS; Dorsey C; LaRatta N; Weissbrot H; Luning Prak ET; Tsao P; Paskalis D; Sportelli P; Miskin HP; Weiss MS; Svoboda J; Brander DM
Blood; 2021 May; 137(20):2817-2826. PubMed ID: 33259589
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
[TBL] [Abstract][Full Text] [Related]
8. Umbralisib: First Approval.
Dhillon S; Keam SJ
Drugs; 2021 May; 81(7):857-866. PubMed ID: 33797740
[TBL] [Abstract][Full Text] [Related]
9. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
Wang Z; Zhou H; Xu J; Wang J; Niu T
Front Immunol; 2022; 13():1070660. PubMed ID: 36685572
[TBL] [Abstract][Full Text] [Related]
11. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.
Maharaj K; Powers JJ; Achille A; Mediavilla-Varela M; Gamal W; Burger KL; Fonseca R; Jiang K; Miskin HP; Maryanski D; Monastyrskyi A; Duckett DR; Roush WR; Cleveland JL; Sahakian E; Pinilla-Ibarz J
Blood Adv; 2020 Jul; 4(13):3072-3084. PubMed ID: 32634240
[TBL] [Abstract][Full Text] [Related]
12. The evidence to date on umbralisib for the treatment of refractory marginal zone lymphoma and follicular lymphoma.
Schweitzer J; Hoffman M; Graf SA
Expert Opin Pharmacother; 2022 Apr; 23(5):535-541. PubMed ID: 35209784
[TBL] [Abstract][Full Text] [Related]
13. Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study.
Goto H; Izutsu K; Ennishi D; Mishima Y; Makita S; Kato K; Hanaya M; Hirano S; Narushima K; Teshima T; Nagai H; Ishizawa K
Int J Hematol; 2022 Dec; 116(6):911-921. PubMed ID: 36107394
[TBL] [Abstract][Full Text] [Related]
14. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Lunning M; Vose J; Nastoupil L; Fowler N; Burger JA; Wierda WG; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Sportelli P; Miskin HP; Weiss MS; O'Brien S
Blood; 2019 Nov; 134(21):1811-1820. PubMed ID: 31558467
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204).
Phillips TJ; Avigdor A; Gurion R; Patti C; Corradini P; Tani M; Mehta A; Lossos IS; Zinzani PL; Thieblemont C; Jurczak W; Zheng F; Rappold E; Zhao W; Jiang P; Johnson P
Blood Adv; 2024 Feb; 8(4):867-877. PubMed ID: 38113459
[TBL] [Abstract][Full Text] [Related]
16. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Neelapu SS; Chavez JC; Sehgal AR; Epperla N; Ulrickson M; Bachy E; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Oluwole OO; Yakoub-Agha I; Khanal R; Rosenblatt J; Korn R; Peng W; Lui C; Wulff J; Shen R; Poddar S; Jung AS; Miao H; Beygi S; Jacobson CA
Blood; 2024 Feb; 143(6):496-506. PubMed ID: 37879047
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Kirschbaum M; Frankel P; Popplewell L; Zain J; Delioukina M; Pullarkat V; Matsuoka D; Pulone B; Rotter AJ; Espinoza-Delgado I; Nademanee A; Forman SJ; Gandara D; Newman E
J Clin Oncol; 2011 Mar; 29(9):1198-203. PubMed ID: 21300924
[TBL] [Abstract][Full Text] [Related]
18. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
19. A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
Strati P; Coleman M; Champion R; Ma S; Patti C; Levy MY; Lossos IS; Geethakumari PR; Lam S; Calvo R; Higgins K; Budde LE
Br J Haematol; 2022 Oct; 199(1):76-85. PubMed ID: 35861370
[TBL] [Abstract][Full Text] [Related]
20. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak WJ; Flinn IW; Flowers CR; Martin P; Viardot A; Blum KA; Goy AH; Davies AJ; Zinzani PL; Dreyling M; Johnson D; Miller LL; Holes L; Li D; Dansey RD; Godfrey WR; Salles GA
N Engl J Med; 2014 Mar; 370(11):1008-18. PubMed ID: 24450858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
